CTLA4 and melanoma: To further assess the effectiveness and robustness of pTuneos, we also applied the whole pipeline to three independent datasets comprising anti-CTLA-4-treated melanoma patients and anti-PD-1-treated lung cancer patients to compare the identified neoantigen profile with patient survival patterns [4–6].